QS Investors’s iBio IBIO Stock Holding History

QS Investors’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$107K	Hold	141	–	–	﹤0.01%	1086
2021 Q1	$109K	Hold	141	–	–	﹤0.01%	1152
2020 Q4	$74K	Buy	+141	New	+$115K	﹤0.01%	1150

Other funds holding IBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

QS Investors's IBIO Position: Q2 2021 in Review

QS Investors held its iBio (IBIO) position steady in Q2 2021 at 141 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

QS Investors first reported a position in IBIO in Q4 2020 and has held it in 3 quarters since. The position peaked at $109K in Q1 2021. 83 funds tracked by Wall St. Rank hold IBIO as of Q2 2021.

QS Investors held 141 shares of iBio worth $107K as of Q2 2021.
QS Investors left its iBio share count unchanged in Q2 2021.
iBio made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #1086 holding.
QS Investors first reported a position in iBio in Q4 2020 and has held it in 3 quarters since.
QS Investors's iBio position peaked at $109K in Q1 2021.
83 funds tracked by Wall St. Rank held iBio as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.